Interventions for the prevention of recurrent erysipelas and cellulitis.
Identifieur interne : 000469 ( Main/Exploration ); précédent : 000468; suivant : 000470Interventions for the prevention of recurrent erysipelas and cellulitis.
Auteurs : Adam Dalal ; Marina Eskin-Schwartz ; Daniel Mimouni ; Sujoy Ray ; Walford Days ; Emmilia Hodak ; Leonard Leibovici ; Mical PaulSource :
- The Cochrane database of systematic reviews [ 1469-493X ] ; 2017.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen, Antibactériens (effets indésirables), Antibactériens (usage thérapeutique), Antibioprophylaxie (effets indésirables), Benzathine benzylpénicilline (effets indésirables), Benzathine benzylpénicilline (usage thérapeutique), Bras, Cellulite sous-cutanée (), Dermatoses de la jambe (), Essais contrôlés randomisés comme sujet, Hospitalisation (), Humains, Phénoxyméthylpénicilline (effets indésirables), Phénoxyméthylpénicilline (usage thérapeutique), Prévention secondaire (), Récidive, Sujet âgé, Sélénium (usage thérapeutique), Érysipèle (), Érythromycine (effets indésirables), Érythromycine (usage thérapeutique).
- MESH :
- effets indésirables : Antibactériens, Antibioprophylaxie, Benzathine benzylpénicilline, Phénoxyméthylpénicilline, Érythromycine.
- usage thérapeutique : Antibactériens, Benzathine benzylpénicilline, Phénoxyméthylpénicilline, Sélénium, Érythromycine.
- Adulte d'âge moyen, Bras, Cellulite sous-cutanée, Dermatoses de la jambe, Essais contrôlés randomisés comme sujet, Hospitalisation, Humains, Prévention secondaire, Récidive, Sujet âgé, Érysipèle.
English descriptors
- KwdEn :
- Aged, Anti-Bacterial Agents (adverse effects), Anti-Bacterial Agents (therapeutic use), Antibiotic Prophylaxis (adverse effects), Arm, Cellulitis (prevention & control), Erysipelas (prevention & control), Erythromycin (adverse effects), Erythromycin (therapeutic use), Hospitalization (statistics & numerical data), Humans, Leg Dermatoses (prevention & control), Middle Aged, Penicillin G Benzathine (adverse effects), Penicillin G Benzathine (therapeutic use), Penicillin V (adverse effects), Penicillin V (therapeutic use), Randomized Controlled Trials as Topic, Recurrence, Secondary Prevention (methods), Selenium (therapeutic use).
- MESH :
- chemical , adverse effects : Anti-Bacterial Agents, Erythromycin, Penicillin G Benzathine, Penicillin V.
- chemical , therapeutic use : Anti-Bacterial Agents, Erythromycin, Penicillin G Benzathine, Penicillin V, Selenium.
- adverse effects : Antibiotic Prophylaxis.
- methods : Secondary Prevention.
- prevention & control : Cellulitis, Erysipelas, Leg Dermatoses.
- statistics & numerical data : Hospitalization.
- Aged, Arm, Humans, Middle Aged, Randomized Controlled Trials as Topic, Recurrence.
Abstract
Erysipelas and cellulitis (hereafter referred to as 'cellulitis') are common bacterial skin infections usually affecting the lower extremities. Despite their burden of morbidity, the evidence for different prevention strategies is unclear.
DOI: 10.1002/14651858.CD009758.pub2
PubMed: 28631307
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000135
- to stream PubMed, to step Curation: 000135
- to stream PubMed, to step Checkpoint: 000135
- to stream Ncbi, to step Merge: 009211
- to stream Ncbi, to step Curation: 009211
- to stream Ncbi, to step Checkpoint: 009211
- to stream Main, to step Merge: 000469
- to stream Main, to step Curation: 000469
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Interventions for the prevention of recurrent erysipelas and cellulitis.</title><author><name sortKey="Dalal, Adam" sort="Dalal, Adam" uniqKey="Dalal A" first="Adam" last="Dalal">Adam Dalal</name><affiliation><nlm:affiliation>Department of Dermatology, Beilinson Hospital, Rabin Medical Center, 39 Jabotinski Street, Petah Tikva, Israel, 49100.</nlm:affiliation><wicri:noCountry code="subField">49100</wicri:noCountry></affiliation></author><author><name sortKey="Eskin Schwartz, Marina" sort="Eskin Schwartz, Marina" uniqKey="Eskin Schwartz M" first="Marina" last="Eskin-Schwartz">Marina Eskin-Schwartz</name></author><author><name sortKey="Mimouni, Daniel" sort="Mimouni, Daniel" uniqKey="Mimouni D" first="Daniel" last="Mimouni">Daniel Mimouni</name></author><author><name sortKey="Ray, Sujoy" sort="Ray, Sujoy" uniqKey="Ray S" first="Sujoy" last="Ray">Sujoy Ray</name></author><author><name sortKey="Days, Walford" sort="Days, Walford" uniqKey="Days W" first="Walford" last="Days">Walford Days</name></author><author><name sortKey="Hodak, Emmilia" sort="Hodak, Emmilia" uniqKey="Hodak E" first="Emmilia" last="Hodak">Emmilia Hodak</name></author><author><name sortKey="Leibovici, Leonard" sort="Leibovici, Leonard" uniqKey="Leibovici L" first="Leonard" last="Leibovici">Leonard Leibovici</name></author><author><name sortKey="Paul, Mical" sort="Paul, Mical" uniqKey="Paul M" first="Mical" last="Paul">Mical Paul</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28631307</idno><idno type="pmid">28631307</idno><idno type="doi">10.1002/14651858.CD009758.pub2</idno><idno type="wicri:Area/PubMed/Corpus">000135</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000135</idno><idno type="wicri:Area/PubMed/Curation">000135</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000135</idno><idno type="wicri:Area/PubMed/Checkpoint">000135</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000135</idno><idno type="wicri:Area/Ncbi/Merge">009211</idno><idno type="wicri:Area/Ncbi/Curation">009211</idno><idno type="wicri:Area/Ncbi/Checkpoint">009211</idno><idno type="wicri:Area/Main/Merge">000469</idno><idno type="wicri:Area/Main/Curation">000469</idno><idno type="wicri:Area/Main/Exploration">000469</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Interventions for the prevention of recurrent erysipelas and cellulitis.</title><author><name sortKey="Dalal, Adam" sort="Dalal, Adam" uniqKey="Dalal A" first="Adam" last="Dalal">Adam Dalal</name><affiliation><nlm:affiliation>Department of Dermatology, Beilinson Hospital, Rabin Medical Center, 39 Jabotinski Street, Petah Tikva, Israel, 49100.</nlm:affiliation><wicri:noCountry code="subField">49100</wicri:noCountry></affiliation></author><author><name sortKey="Eskin Schwartz, Marina" sort="Eskin Schwartz, Marina" uniqKey="Eskin Schwartz M" first="Marina" last="Eskin-Schwartz">Marina Eskin-Schwartz</name></author><author><name sortKey="Mimouni, Daniel" sort="Mimouni, Daniel" uniqKey="Mimouni D" first="Daniel" last="Mimouni">Daniel Mimouni</name></author><author><name sortKey="Ray, Sujoy" sort="Ray, Sujoy" uniqKey="Ray S" first="Sujoy" last="Ray">Sujoy Ray</name></author><author><name sortKey="Days, Walford" sort="Days, Walford" uniqKey="Days W" first="Walford" last="Days">Walford Days</name></author><author><name sortKey="Hodak, Emmilia" sort="Hodak, Emmilia" uniqKey="Hodak E" first="Emmilia" last="Hodak">Emmilia Hodak</name></author><author><name sortKey="Leibovici, Leonard" sort="Leibovici, Leonard" uniqKey="Leibovici L" first="Leonard" last="Leibovici">Leonard Leibovici</name></author><author><name sortKey="Paul, Mical" sort="Paul, Mical" uniqKey="Paul M" first="Mical" last="Paul">Mical Paul</name></author></analytic><series><title level="j">The Cochrane database of systematic reviews</title><idno type="eISSN">1469-493X</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Anti-Bacterial Agents (adverse effects)</term><term>Anti-Bacterial Agents (therapeutic use)</term><term>Antibiotic Prophylaxis (adverse effects)</term><term>Arm</term><term>Cellulitis (prevention & control)</term><term>Erysipelas (prevention & control)</term><term>Erythromycin (adverse effects)</term><term>Erythromycin (therapeutic use)</term><term>Hospitalization (statistics & numerical data)</term><term>Humans</term><term>Leg Dermatoses (prevention & control)</term><term>Middle Aged</term><term>Penicillin G Benzathine (adverse effects)</term><term>Penicillin G Benzathine (therapeutic use)</term><term>Penicillin V (adverse effects)</term><term>Penicillin V (therapeutic use)</term><term>Randomized Controlled Trials as Topic</term><term>Recurrence</term><term>Secondary Prevention (methods)</term><term>Selenium (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Antibactériens (effets indésirables)</term><term>Antibactériens (usage thérapeutique)</term><term>Antibioprophylaxie (effets indésirables)</term><term>Benzathine benzylpénicilline (effets indésirables)</term><term>Benzathine benzylpénicilline (usage thérapeutique)</term><term>Bras</term><term>Cellulite sous-cutanée ()</term><term>Dermatoses de la jambe ()</term><term>Essais contrôlés randomisés comme sujet</term><term>Hospitalisation ()</term><term>Humains</term><term>Phénoxyméthylpénicilline (effets indésirables)</term><term>Phénoxyméthylpénicilline (usage thérapeutique)</term><term>Prévention secondaire ()</term><term>Récidive</term><term>Sujet âgé</term><term>Sélénium (usage thérapeutique)</term><term>Érysipèle ()</term><term>Érythromycine (effets indésirables)</term><term>Érythromycine (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Anti-Bacterial Agents</term><term>Erythromycin</term><term>Penicillin G Benzathine</term><term>Penicillin V</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Bacterial Agents</term><term>Erythromycin</term><term>Penicillin G Benzathine</term><term>Penicillin V</term><term>Selenium</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Antibiotic Prophylaxis</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antibactériens</term><term>Antibioprophylaxie</term><term>Benzathine benzylpénicilline</term><term>Phénoxyméthylpénicilline</term><term>Érythromycine</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Secondary Prevention</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Cellulitis</term><term>Erysipelas</term><term>Leg Dermatoses</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Hospitalization</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antibactériens</term><term>Benzathine benzylpénicilline</term><term>Phénoxyméthylpénicilline</term><term>Sélénium</term><term>Érythromycine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Arm</term><term>Humans</term><term>Middle Aged</term><term>Randomized Controlled Trials as Topic</term><term>Recurrence</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Bras</term><term>Cellulite sous-cutanée</term><term>Dermatoses de la jambe</term><term>Essais contrôlés randomisés comme sujet</term><term>Hospitalisation</term><term>Humains</term><term>Prévention secondaire</term><term>Récidive</term><term>Sujet âgé</term><term>Érysipèle</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Erysipelas and cellulitis (hereafter referred to as 'cellulitis') are common bacterial skin infections usually affecting the lower extremities. Despite their burden of morbidity, the evidence for different prevention strategies is unclear.</div></front></TEI><affiliations><list></list><tree><noCountry><name sortKey="Dalal, Adam" sort="Dalal, Adam" uniqKey="Dalal A" first="Adam" last="Dalal">Adam Dalal</name><name sortKey="Days, Walford" sort="Days, Walford" uniqKey="Days W" first="Walford" last="Days">Walford Days</name><name sortKey="Eskin Schwartz, Marina" sort="Eskin Schwartz, Marina" uniqKey="Eskin Schwartz M" first="Marina" last="Eskin-Schwartz">Marina Eskin-Schwartz</name><name sortKey="Hodak, Emmilia" sort="Hodak, Emmilia" uniqKey="Hodak E" first="Emmilia" last="Hodak">Emmilia Hodak</name><name sortKey="Leibovici, Leonard" sort="Leibovici, Leonard" uniqKey="Leibovici L" first="Leonard" last="Leibovici">Leonard Leibovici</name><name sortKey="Mimouni, Daniel" sort="Mimouni, Daniel" uniqKey="Mimouni D" first="Daniel" last="Mimouni">Daniel Mimouni</name><name sortKey="Paul, Mical" sort="Paul, Mical" uniqKey="Paul M" first="Mical" last="Paul">Mical Paul</name><name sortKey="Ray, Sujoy" sort="Ray, Sujoy" uniqKey="Ray S" first="Sujoy" last="Ray">Sujoy Ray</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000469 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000469 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:28631307
|texte= Interventions for the prevention of recurrent erysipelas and cellulitis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:28631307" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |